Immuno-oncology company Imugene
(ASX:IMU) will present data from its Phase Ib study of its HER-Vaxx cancer vaccine at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois in the US at the end of this month.
The abstract, number 4030, will be presented by Dr Yee Chao, Director of the Department of Oncology at the Veterans General Hospital in Taipei in Taiwan and a lead investigator in the Phase 1b study.
His presentation will be featured at the ASCO Gastrointestinal (Noncolorectal) Cancer Session.
The study which completed enrolment in 2018 has met all its primary endpoints. .
HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in cancers such as gastric, breast, ovarian, lung and pancreatic cancers.
Shares in Imugene
(ASX:IMU) are trading 5.88 per cent higher at 1.8 cents.
